Reverse merger will see Achieve Life Science acquired by OncoGenex

6 January 2017
mergers-acquisitions-big

Shares in the USA-based biotech firm OncoGenex Pharmaceuticals (Nasdaq: OGXI) gained more than 50% in pre-market trading, following the announcement of a reverse merger with the privately held pharmaceutical company Achieve Life Science.

The proposed all-stock deal will see Achieve acquired by OncoGenex. Equity holders in the former will own 75% of the new company, the latter 25%.

Following completion of the merger, OncoGenex will be renamed Achieve Life Sciences Inc.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology